Targeted screening for congenital cytomegalovirus: A micro‐costing analysis

Aim We aimed to determine the cost and potential cost‐savings of delivering a targeted congenital cytomegalovirus (cCMV) screening programme through a universal newborn hearing screening (UNHS) programme to detect cCMV‐related hearing loss in infants from Victoria, Australia. Methods We completed a micro‐costing analysis from a health‐care perspective using data from a targeted cCMV screening programme piloted between June 2019 and March 2020. The programme involved collection of saliva samples to test for cCMV in infants who: received a ‘refer’ result on their second newborn hearing screen; were aged 21 days or less; and born at one of four maternity hospitals in Victoria, Australia. All costs to complete targeted cCMV screening were recorded in Australian 2020 dollars. Potential costs and benefits of adding targeted cCMV screening to the pre‐existing UNHS programme were compared to when no screening was available up to 18 years to determine the likely cost or cost savings. Results The cost of adding targeted cCMV screening to Victoria's UNHS is $202 per infant screened. The total cost per positive case identified is $21 456. The overall cost of adding targeted salivary cCMV screening at the point of a second ‘refer’ result on the UNHS programme in Victoria's four largest hospitals is estimated to be $28 966 for the first year. Conclusion Targeted screening for cCMV provides families the opportunity to detect and, if appropriate, treat cCMV in the first month of life in line with current recommendations. It falls within the range between cost neutral and cost saving.